Lantheus (LNTH) Stock
Publicly traded company. Here's the price, business snapshot, and what's worth knowing about Lantheus in October 2026.
Lantheus Holdings, Inc. is a radiopharmaceutical-focused company, dedicated to helping clinicians find, fight, and follow disease to deliver better patient outcomes. Its product categories include oncology, neurology, cardiology, and strategic partnerships and others. Its products include PYLARIFY, Neuraceq, and DEFINITY. PYLARIFY TruVu is indicated for PET imaging of PSMA-positive lesions in men with prostate cancer with suspected metastasis who are candidates for initial definitive therapy, or suspected recurrence based on elevated serum prostate-specific antigen (PSA). Neuraceq is an Alzheimer's disease radiodiagnostic. Its commercial products are used by cardiologists, internists, neurologists, nuclear medicine physicians, oncologists, radiologists, sonographers, technologists, and urologists across a range of clinical care settings. Its diagnostic products provide information that enables healthcare professionals (HCPs) to better detect, characterize, or rule out diseases.
Lantheus (LNTH) Stock Forecast
Analyst price target, next 12 months
$107.26
+7.5% vs today's $99.80
Price range over the last 12 months
Close to its 12-month high
Analysts covering Lantheus have a consensus 12-month target of $107.26, above the current price of $99.80.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 25 Oct 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts suggest holding Lantheus stock with a target price of $107.26, indicating slight growth potential.
Financial Health
Lantheus Holdings is performing well with strong revenue and cash flow, indicating good financial stability.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
